Key points
- Until about ten years ago, chemotherapy was the mainstay of CLL treatment, and in its time it lengthened patients' lives [1].
- Targeted tablets did better in direct comparison: in patients aged 70 or under, longer life and fewer serious infections [3, 4].
- In older people too, the tablets controlled the disease far better than chemotherapy [2, 6].
- European guidelines now build CLL treatment on these drugs; if only chemotherapy is offered, ask why [10].
Chapter one: the chemotherapy era
For years, CLL treatment had two faces. For older people, a simple chemotherapy tablet called chlorambucil; and for fitter patients, a stronger combination called FCR (two chemotherapy drugs with the antibody rituximab).
In 2010, FCR was a big step: it delayed the disease getting worse and patients lived a little longer [1]. But it came at a heavy price: severe drops in white blood cells became more common, and this treatment had only been tested in fit patients [1].
Chapter two: the tablet that changed course
Scientists found that CLL cells depend on an internal "switch" called BTK to survive. Ibrutinib tablets turn this switch off.
In older people: when ibrutinib was compared with chlorambucil, two years later almost everyone who had taken ibrutinib was alive; with chemotherapy, more patients had died [2]. In another study, four years on, the disease had stayed quiet in most of those taking the tablet; with chemotherapy, the disease had got worse again in half of patients [5, 6].
In younger people: the most important test was whether the tablet could beat even FCR in patients aged 70 or under. The answer was clear: three years later, almost everyone who had taken the tablet was alive; with chemotherapy, more patients had died. Serious infections were also halved with the tablet [3]. After nearly 6 years this survival advantage still held [4].
Chapter three: a treatment that ends
One worry remained: did patients have to take tablets for the rest of their lives? A second tablet, venetoclax, brought the answer. Venetoclax with an antibody is given for only about a year and then stopped; in patients who also had other illnesses, the disease usually stayed quiet for more than 6 years after this one year of treatment; nearly twice as long as with chemotherapy [7].
Taking two tablets together (ibrutinib and venetoclax) for about 15 months also kept the disease quiet far better than chemotherapy [8]. In a large study in the UK, doctors used a very precise blood test to decide how long to continue these two tablets. Five years on, the disease was quiet in almost everyone, and fewer patients had died than with chemotherapy [9].
Where are we today?
The 2026 European guideline builds the first treatment of CLL on these targeted drugs and prefers fixed-duration treatment for most patients [10]. One thing has not changed: treatment starts only once the disease has become active; quiet disease needs only follow-up [11].
Read a practical guide to the options in The best treatment for CLL.
Especially if you are young or your disease has only just needed treatment:
- Ask why a targeted tablet was not chosen for you.
- Ask whether the TP53 and IGHV gene tests have been done [10].
- If you do not get a clear answer, get a second opinion from a haematologist-oncologist.
Do not stop or change treatment yourself; raise these questions with your doctor.
Frequently asked questions
Don't targeted tablets have side effects?
I have already had chemotherapy; is it too late?
No. If the disease comes back, targeted tablets also work in later treatments; for example, in previously treated patients ibrutinib did better than the treatment it was compared with [12]. Talk to your doctor.
Does chemotherapy have no place at all?
It may be used in a few cases, but for most patients targeted tablets are the first choice [10].
For physicians
Show detailsHide
CLL8: FCR versus FC, 3-year PFS 65% versus 45% (HR 0.56) and OS 87% versus 83% [1]. RESONATE-2: ibrutinib versus chlorambucil, HR for progression 0.16 and 2-year OS 98% versus 85% [2]. E1912: IR versus FCR at ≤70 years, 3-year OS 98.8% versus 91.5% (HR 0.17), grade ≥3 infection 10.5% versus 20.3% [3]; long-term follow-up OS HR 0.47 [4]. A041202: 2-year PFS 87% versus 74% with BR [5]; at 48 months 76% versus 47% [6]. CLL14: VenO median PFS 76.2 versus 36.4 months [7]. GLOW: 42-month PFS 74.6% versus 24.8% [8]. FLAIR: MRD-guided I+V versus FCR, HR for progression 0.13 and HR for death 0.26 [9]. EHA 2026: fixed-duration regimens are preferred in patients without a TP53 abnormality [10].
Scientific evidence
Show detailsHide
Scientific evidence
9 itemsAddition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia
EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Read more
Related cancer types
Treatment guides
References
12 referencesShow all references, 12 with a study cardClose the reference list
Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.
- 1
- 2
- 3
- 4
- 5Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
- 6
- 7Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study
- 8Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial
- 9
- 10
- 11iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
- 12Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.
Printed from the website; the full and up-to-date version: https://drdabiri.com/en/articles/cll-chemotherapy-vs-targeted/
